Prime Highlights
- Jagsonpal Pharmaceuticals signs a deal to acquire an 85 per cent stake in Aequitas Healthcare for Rs 20.8 crore.
- The acquisition marks Jagsonpal’s strategic entry into India’s hospital-focused pharmaceutical distribution segment.
Key Facts
- Aequitas Healthcare, founded in 2017, reported revenue of Rs 53 crore in FY26.
- Aequitas’ current directors will retain the remaining 15 per cent stake and stay involved with the business.
Background
Jagsonpal Pharmaceuticals has entered into a definitive agreement to buy an 85% interest in Mumbai-based company Aequitas Healthcare Private Limited as a part of its new strategy for entering into the hospital-oriented pharmaceuticals distribution market in India.
This will help the company enter the hospital business strategically and achieve its long-term objective of making itself more prominent in India’s healthcare sector.
The company Aequitas Healthcare was set up in 2017 and works on providing pharmaceuticals to leading hospital chains. The company posted revenue of Rs 53 crore in FY26 and has built ties with several major institutional accounts.
Under the agreement, Jagsonpal will pay Rs 20.8 crore for the 85 per cent stake, funded entirely through internal accruals. Aequitas’ existing directors will retain the remaining 15 per cent and continue to be part of the business.
Jagsonpal Managing Director Manish Gupta said the acquisition marked an important strategic milestone for the company, giving it a ready platform to build a meaningful presence in the hospital segment, which now makes up close to 10 per cent of pharma industry sales and continues to grow at a faster pace.
He said Jagsonpal’s established brand portfolio would benefit from Aequitas’ strong institutional relationships, creating long-term value for shareholders.
Chief Operating Officer Amrut Medhekar described the deal as a structurally transformative step that shifts Jagsonpal from a traditional retail prescription business toward an omnichannel specialty healthcare model in India.
He said the move reflected the company’s long-term commitment to building a scalable, high-quality healthcare delivery business, with plans to focus on operational efficiency, disciplined execution and patient-centred growth.
